SCHEMBL7134128

SCHEMBL7134128

COc1ccc2c(c1CN)C(S(=O)(=O)c1ccccc1)CS2(O)O

nearest known ligand 0.36

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.35
ALDH1A1 P00352 2/20 0.35
HSD11B1 P28845 2/20 0.34
TP53 P04637 2/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HTR6 P50406 2/20 0.33
MAPT P10636 2/20 0.32
KDM4E B2RXH2 1/20 0.32
GAA P10253 1/20 0.32
MEN1 O00255 1/20 0.31
KMT2A Q03164 1/20 0.31
QRFPR Q96P65 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HTT P42858 1/20 0.31
MAPK1 P28482 1/20 0.31
PTK2B Q14289 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL7250224 0.99 POLB (0.34) POLBALDH1A1HSD11B1TP53L3MBTL1
SCHEMBL7134132 0.88 HTR6 (0.34) POLBALDH1A1HSD11B1TP53L3MBTL1
Hydrochloric Acid SCHEMBL7250221 0.87 HTR6 (0.33) POLBALDH1A1HSD11B1TP53L3MBTL1
SCHEMBL7129408 0.86 VEGFA (0.35) POLBALDH1A1L3MBTL1MAPTSMN1; SMN2
Hydrochloric Acid SCHEMBL7131073 0.85 AOC3 (0.36) POLBALDH1A1L3MBTL1MAPTSMN1; SMN2
SCHEMBL7137251 0.83 HTR2A (0.34)
Hydrochloric Acid SCHEMBL7248156 0.83 HTR2A (0.34)
SCHEMBL7126347 0.81 HTR6 (0.39) POLBALDH1A1HSD11B1TP53L3MBTL1
SCHEMBL7126887 0.80 DRD2 (0.36) POLBALDH1A1TP53L3MBTL1KMT2A
SCHEMBL7134098 0.77 HTR6 (0.37) POLBALDH1A1HSD11B1TP53L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient KONISHI MIKIO (JP) 2003-04-17 US claimed
US-6420391-B1 PREVENTION AND/OR TREATMENT OF VARIOUS INFLAMMATORY DISEASES, SEPSIS, MULTIPLE MYELOMA, PLASMA CELL LEUKEMIA, OSTEOPOROSIS, CACHEXIA, PSORIASIS, NEPHRITIS, RENAL CELL CARCINOMA, KAPOSI'S SARCOMA, RHEUMATOID ARTHRITIS, GAMMOPATHY, CASTLEMAN'S ONO PHARMACEUTICAL CO., LTD. (JP) 2002-07-16 US claimed
EP-1067128-A1 FUSED THIOPHENE DERIVATIVES AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT ONO PHARMACEUTICAL CO., LTD. (JP) 2001-01-10 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030073706-A1 Fused thiophone derivatives and drugs containing the same as the active ingredient TPMT, CD47, THPO POLB 4703/4885ALDH1A1 3159/4885HSD11B1 1864/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.